We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555581

CAS#: 889860-85-9

Description: GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(–) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 550 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

GAT229, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555581
Name: GAT229
CAS#: 889860-85-9
Chemical Formula: C22H18N2O2
Exact Mass: 342.1368
Molecular Weight: 342.398
Elemental Analysis: C, 77.17; H, 5.30; N, 8.18; O, 9.35

Synonym: GAT229; GAT-229; GAT 229;

IUPAC/Chemical Name: 3-[(1S)-2-nitro-1-phenylethyl]-2-phenyl-1H-indole


InChi Code: InChI=1S/C22H18N2O2/c25-24(26)15-19(16-9-3-1-4-10-16)21-18-13-7-8-14-20(18)23-22(21)17-11-5-2-6-12-17/h1-14,19,23H,15H2/t19-/m0/s1

SMILES Code: O=[N+](C[C@H](C1=C(C2=CC=CC=C2)NC3=C1C=CC=C3)C4=CC=CC=C4)[O-]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology. 2019 Jun;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. Epub 2019 Mar 30. PubMed PMID: 30940536; PubMed Central PMCID: PMC6544167.

2: Mitjavila J, Yin D, Kulkarni PM, Zanato C, Thakur GA, Ross R, Greig I, Mackie K, Straiker A. Enantiomer-specific positive allosteric modulation of CB(1) signaling in autaptic hippocampal neurons. Pharmacol Res. 2018 Mar;129:475-481. doi: 10.1016/j.phrs.2017.11.019. Epub 2017 Nov 20. PubMed PMID: 29158048; PubMed Central PMCID: PMC5828971.

3: Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM. The In Vivo Effects of the CB(1)-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. doi: 10.1089/jop.2017.0037. Epub 2017 Jul 18. PubMed PMID: 28719234; PubMed Central PMCID: PMC5649393.

4: Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, Thakur GA. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203. doi: 10.1021/acschemneuro.6b00310. Epub 2017 Feb 7. PubMed PMID: 28103441.